Positron emission tomography in lung cancer

General Thoracic and Cardiovascular Surgery

Volumn 57, Issue 4, 2009, Pages 184-191

  Nomori, Hiroaki ^a,b   Ohba, Yasuomi ^a   Yoshimoto, Kentaro ^a   Shibata, Hidekatsu ^a   Shiraishi, Kenji ^a   Mori, Takeshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; Lung cancer; Positron emission tomography; Prognosis; Staging

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; HUMAN; LUNG ADENOCARCINOMA; LUNG NODULE; LYMPH NODE METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; QUANTITATIVE ANALYSIS; REVIEW; TREATMENT RESPONSE;

COMBINED MODALITY THERAPY; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 64749093543     PISSN: 18636705     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11748-008-0371-3     Document Type: Review

References (62)

1. 18F] fluorodeoxy-glucose Ann Thorac Surg 58 698 703
2. E.F. Patz V.J. Lowe J.M. Hoffman S.S. Paine P. Burrowes R.E. Coleman 1993 Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning Radiology 188 487 490
3. N.C. Gupta J. Maloof E. Gunel 1996 Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET J Nucl Med 37 943 948
4. N. Gupta H. Gill G. Graeber H. Bishop J. Hurst T. Stephens 1998 Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions Chest 114 1105 1111
5. S.S. Gambhir J.E. Shepherd B.D. Shah E. Hart C.K. Hoh P.E. Valk 1998 Analytical decision model for the cost-effectiveness management of solitary pulmonary nodules J Clin Oncol 16 2113 2125
6. M.K. Gould C.C. Maclean W.G. Kuschner C.E. Rydzak D.K. Owens 2001 Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis JAMA 285 914 924
7. N.A. Dewan N.C. Gupta L.S. Redepenning J.J. Phalen M.P. Frick 1993 Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules: potential role in evaluation and management Chest 104 997 1002
8. K. Higashi Y. Ueda H. Seki K. Yuasa M. Oguchi T. Noguchi 1998 Fluorine-18-FDG PET imaging is negative in bronchioloalveolar carcinoma J Nucl Med 39 1016 1020
9. A. Imdahl S. Jenkner I. Brink E. Nitzsche E. Stoelben E. Moser 2001 Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions Eur J Cardiothorac Surg 20 324 329
10. R.E. Coleman 1999 PET in lung cancer J Nucl Med 40 814 820
11. T.C. McLoud 2002 Imaging techniques for diagnosis and staging of lung cancer Clin Chest Med 23 123 136
12. V.J. Lowe J.W. Fletcher L. Gobar M. Lawson P. Kirchner P. Valk 1998 Prospective investigation of positron emission tomography in lung nodules J Clin Oncol 16 1075 1084
13. H. Nomori K. Watanabe T. Ohtsuka T. Naruke K. Suemasu K. Uno 2004 Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images Lung Cancer 45 19 27
14. V.J. Lowe J.M. Hoffman D.M. DeLong E.F. Patz R.E. Coleman 1994 Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities J Nucl Med 35 1771 1776
15. K.R. Zasadny R.L. Wahl 1993 Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction Radiology 189 847 850
16. C.K. Kim N.C. Gupta B. Chandramouli A. Alavi 1994 Standarized uptake values of FDG: body surface area correction is preferable to body weight correction J Nucl Med 35 164 167
17. C.K. Kim N.C. Gupta 1996 Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction Nucl Med Commun 17 890 894
18. P. Lindholm H. Minn S. Leskinen-Kallio J. Bergman U. Ruotsalainen H. Joensuu 1993 Influence of the blood glucose concentration on FDG uptake in cancer: a PET study J Nucl Med 34 1 6
19. K.J. Langen U. Braun E. Rota Kops H. Herxog T. Kuwert B. Nebeling 1993 The influence of plasma glucose levels of fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas J Nucl Med 34 355 359
20. L.M. Hamberg G.I. Hunter N.M. Alpert N.C. Choi J.W. Babich A.J. Fischman 1994 The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 35 1308 1312
21. 18F-FDG to detect residual disease after therapy for malignant lymphoma Nucl Med Commun 19 1055 1063
22. Y. Menda D.L. Bushnell M.T. Madsen K. McLaughlin D. Kahn K.H. Kernstine 2001 Evaluation of various corrections to the standardized uptake value for diagnosis of pulmonary malignancy Nucl Med Commun 22 1077 1081
23. 18F-FDG PET Nucl Med 27 7 13
24. H. Nomori K. Watanabe T. Ohtsuka T. Naruke K. Suemasu K. Uno 2005 Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size Ann Thorac Surg 79 984 988
25. Ohba Y, Nomori H, Shibata H, Kobayashi H, Mori T, Shiraishi S, et al. Evaluation of semiquantitative analyses of F-18 fluorodeoxyglucose uptake on PET scans for the diagnosis of non-small cell lung cancer less than 3 cm in size. Ann Thorac Surg 2009 (in press).
26. N.C. Gupta W.J. Tamin G.G. Graeber H.A. Bishop G.R. Hobbs 2001 Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging Chest 120 521 527
27. N.C. Gupta M. Geoffrey G.G. Graeber H.A. Bishop 2000 Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (< 1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions Chest 117 773 778
28. T.P. Graeter D. Hellwig K. Hoffman D. Ukena C.M. Kirsch H.J. Schafers 2003 Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy Ann Thorac Surg 75 231 236
29. R. Chin Jr R. Ward J.W. Keyes R.H. Choplin J.C. Reed S. Wallenhaupt 1995 Mediastinal staging of non-small cell lung cancer with positron emission tomography Am J Respir Crit Care Med 152 2090 2096
30. T. Bury P. Paulus A. Dowlati J.L. Corhay T. Weber B. Ghaye 1996 Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer Eur Respir J 9 2560 2564
31. P.E. Valk T.R. Pounds D.M. Hopkins M.K. Haseman G.A. Hofer H.B. Greiss 1995 Staging non-small cell lung cancer by whole-body positron emission tomography imaging Ann Thorac Surg 60 1573 1582
32. B.A. Dwamena S.S. Sonnad J.O. Angobaldo R.L. Wahl 1999 Metastases from non-small cell lung cancer: mediastinal staging in the 1990s: meta-analytic comparison of PET and CT Radiology 213 530 536
33. H. Nomori K. Watanabe T. Ohtsuka T. Naruke K. Suemasu K. Uno 2004 The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer J Thorac Cardiovasc Surg 127 1087 1092
34. A. Ebihara H. Nomori K. Watanabe T. Ohtsuka T. Naruke K. Uno 2006 Characteristics of advantages of positron emission tomography over computed tomography for N-staging in lung cancer patients Jpn J Clin Oncol 36 694 698
35. H. Vesselle J.M. Pugsley E. Vallieres D.E. Wood 2002 The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non-small cell lung cancer J Thorac Cardiovasc Surg 124 511 519
36. K. Higashi Y. Ueda M. Yagishita Y. Arisaka A. Sakurai M. Oguchi 2000 FEG PET measurement of the proliferative potential of non-small cell lung cancer J Nucl Med 41 85 92
37. H. Vesselle R.A. Schmidt J.M. Pugsley M. Li S.G. Kohlmyer E. Vallires 2000 Lung cancer proliferation correlates with [F-18] fluorodeoxyglucose uptake by positron emission tomography Clin Cancer Res 6 3837 3844
38. V. Ahuja R.E. Coleman J. Herndon E.F. Patz 1998 The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma Cancer 83 918 924
39. 18F-fluoro-2-deoxy-glucosepositron emission tomography in non-small cell lung cancer: an analysis of 125 cases J Clin Oncol 17 3201 3206
40. K. Suzuki K. Nagai J. Yoshida M. Nishimura Y. Nishizaki 2001 Predictors of lymph node and intrapulmonary metastasis in clinical stage IA non-small cell lung carcinoma Ann Thorac Surg 72 352 356
41. H. Asamura H. Nakayama H. Kondo R. Tsuchiya Y. Shimosato T. Naruke 1996 Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? J Thorac Cardiovasc Surg 111 1125 1134
42. M. Noguchi A. Morikawa M. Kawasaki Y. Matsuno T. Yamada S. Hirohashi 1995 Small adenocarcinoma of the lung: histologic characteristics and prognosis Cancer 75 2844 2852
43. H. Nomori K. Watanabe T. Ohtsuka T. Naruke K. Suemasu T. Kobayashi 2004 Fluorine 18-tagged fluorodeoxyglucose positron emission tomographic scanning to predict lymph node metastasis, invasiveness, or both, in clinical T1 N0 M0 lung adenocarcinoma J Thorac Cardiovasc Surg 128 396 401
44. K. Watanabe H. Nomori T. Ohtsuka T. Naruke A. Ebihara H. Orikasa 2006 F-18 fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinoma Jpn J Clin Oncol 36 403 409
45. T. Naruke T. Goya R. Tsuchiya K. Suemasu 1998 The importance of surgery of non-small cell carcinoma of lung with mediastinal lymph node metastasis Ann Thorac Surg 46 603 610
46. T. Naruke R. Tsuchiya H. Kondo H. Nakayama H. Asamura 1999 Lymph node sampling in lung cancer: how should it be done? Eur J Cardiothorac Surg 16 S17 S24
47. H. Asamura H. Nakayama H. Kondo R. Tsuchiya T. Naruke 1999 Lobe-specific extent of systemic lymph node dissection for non-small cell lung carcinomas according to a retrospective study of metastases and prognosis J Thorac Cardiovasc Surg 117 1102 1111
48. M.J. Liptay G.A. Masters D.J. Winchester B.L. Edelman B.J. Carrido T.R. Hirshctritt 2000 Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer Ann Thorac Surg 70 384 390
49. H. Nomori H. Horio T. Naruke H. Orikasa K. Yamazaki K. Suemasu 2002 Use of technetium-99m tin colloid for sentinel lymph node identification in non-small cell lung cancer J Thorac Cardiovasc Surg 124 486 492
50. R.J. Cerfolio A.S. Bryant B. Ohja A.A. Bartolucci 2005 The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival J Thorac Cardiovasc Surg 130 151 159
51. M. Sagawa K. Higashi M. Sugita Y. Ueda S. Maeda H. Toga 2006 Fluorodeoxyglucose uptake correlates with the growth pattern of small peripheral pulmonary adenocarcinoma Surg Today 36 230 234
52. 18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathological stage I lung adenocarcinoma Cancer 107 2468 2473
53. R. Rosell J. Gomez-Codina C. Camps J. Maestre J. Padille A. Cantó 1994 A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer N Engl J Med 330 153 158
54. K.S. Lee Y.M. Shim J. Han Y.C. Ahn K. Park K.J. Jung 2000 Primary tumors and mediastinal lymph nodes after neoadjuvant concurrent chemoradiotherapy of lung cancer: serial CT findings with pathologic correlation J Comput Assist Tomogr 24 35 40
55. M. Mateu-Navarro R. Rami-Porta R. Bastus-Piulats L. Cirera-Nogueras G. Gonzalez-Pont 2000 Remediastinoscopy after induction chemotherapy in non-small cell lung cancer Ann Thorac Surg 70 391 395
56. P. Van Schil J. van der Schoot J. Poniewierski M. Pauwels L. Carp P. Germonpré 2002 Remediastinoscopy after neoadjuvant therapy for non-small cell lung cancer Lung Cancer 37 281 285
57. J.F. Vansteenkiste S.G. Stroobants P.R. De Leyn P.J. Dupont E.K. Verbeken 1998 Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study-The Leuven Lung Cancer Group Ann Oncol 9 1193 1198
58. T. Akhurst R.J. Downey M.S. Ginsberg M. Gonen M. Bains R. Korst 2002 An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer Ann Thorac Surg 73 259 264
59. R.J. Cerfolio B. Ojha S. Mukherjee A.H. Pask C.S. Bass C.R. Katholi 2003 Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma J Thorac Cardiovasc Surg 125 938 944
60. J.L. Port M.S. Kent R.J. Korst R. Keresztes M.A. Levin N.K. Altorki 2004 Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer Ann Thorac Surg 77 254 259
61. T. Ohtsuka H. Nomori A. Ebihara K. Watanabe M. Kaji T. Naruke 2006 FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer Ann Thorac Cardiovasc Surg 12 89 94
62. R.J. Cerfolio B. Ojha A.S. Bryant V. Raghuveer J.M. Mountz A.A. Bartolucci 2004 The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with non-small cell lung cancer Ann Thorac Surg 78 1017 1023